Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease

Deligezer, UĞUR; Yaman, Fulya; Darendeliler, Mehmet; Dizdar, Yavuz; Holdenrieder, Stefan; Kovancilar, Muege; Dalay, Nejat

doi:10.1016/j.cca.2010.05.040

Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease

Deligezer U., Yaman F., Darendeliler E., Dizdar Y., Holdenrieder S., Kovancilar M., ...Daha Fazla

CLINICA CHIMICA ACTA, cilt.411, ss.1452-1456, 2010 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 411
Basım Tarihi: 2010
Doi Numarası: 10.1016/j.cca.2010.05.040
Dergi Adı: CLINICA CHIMICA ACTA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1452-1456
Anahtar Kelimeler: Prostate cancer, Metastatic disease, Plasma circulating DNA, Circulating BMP6 mRNA, Free nucleosomes, H3K27 methylation, CELL-FREE DNA, BONE MORPHOGENETIC PROTEIN-6, TUMOR-CELLS, MOLECULAR MARKER, EXPRESSION, PROGRESSION, MECHANISMS, SPREAD, SERUM
İstanbul Üniversitesi Adresli: Evet

Özet

Background: We evaluated the utility of post-treatment plasma levels of the circulating bone-morphogenetic protein-6-specific mRNA (cBMP6 mRNA), cell-free DNA (cf-DNA), apoptotic nucleosomes and Histone H3 lysine 27 trimethylation (H3K27me3), in discriminating metastatic prostate cancer (PCa) from organ confined, locally controlled disease.